Immunovant, Inc.
IMVT
$41.82
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.46% | 11.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.48% | 39.52% | |||
| Operating Income | -0.48% | -39.52% | |||
| Income Before Tax | -1.67% | -38.15% | |||
| Income Tax Expenses | -- | -283.25% | |||
| Earnings from Continuing Operations | -3.63% | -33.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.63% | -33.64% | |||
| EBIT | -0.48% | -39.52% | |||
| EBITDA | -0.48% | -39.56% | |||
| EPS Basic | -2.71% | -19.08% | |||
| Normalized Basic EPS | -0.76% | -23.11% | |||
| EPS Diluted | -2.71% | -19.08% | |||
| Normalized Diluted EPS | -0.76% | -23.11% | |||
| Average Basic Shares Outstanding | 0.90% | 12.23% | |||
| Average Diluted Shares Outstanding | 0.90% | 12.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||